Skip to content

Study · Animal study (in vivo) · ferret · 1990

5 results

Effects of substance P and vasoactive intestinal polypeptide on contractile activity and epithelial transport in the ferret jejunum.

Greenwood B, Doolittle T, See NA, Koch TR, Dodds WJ, Davison JS

Gastroenterology1 Jun 1990Cited by 16 (Europe PMC)

PMID1692548 (opens in a new tab)DOI10.1016/0016-5085(90)91083-i (opens in a new tab)PepBankPUB-01692548
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ferrets, VIP abolished jejunal motor activity.

    In plain wordsIn ferrets, VIP stopped movement of the small intestine.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseJejunal motor activity
    Study

    ferretn: not reported in source

    jejunum, in vivo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Vasoactive intestinal polypeptide abolished motor activity
    1 context sentence
    Summary · context
    The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ferrets, VIP increased jejunal transmural potential difference, and the increase resisted atropine and tetrodotoxin.

    In plain wordsIn ferrets, VIP raised the electrical potential across the small intestine wall, even with atropine or tetrodotoxin present.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseJejunal transmural potential difference
    Study

    ferretn: not reported in source

    jejunum, in vivo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    it induced an increase in transmural potential difference that was atropine and tetrodotoxin resistant.
    1 context sentence
    Summary · context
    The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In ferrets, VIP increased jejunal water secretion.

    In plain wordsIn ferrets, VIP increased water secretion in the small intestine.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseJejunal water secretion
    Study

    ferretn: not reported in source

    jejunum, in vivo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, both peptides increase water secretion.
    1 context sentence
    Summary · context
    The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 04AnimalEndogenous levelAnimal study (in vivo)Other

    In the ferret intestine, immunoreactive VIP was localized to both nerve cell bodies and nerve fibers.

    In plain wordsIn ferrets, the body's own VIP was found in nerve cell bodies and nerve fibers of the intestine.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableLocation of VIP immunoreactivity in the intestine
    Study

    ferretn: not reported in source

    jejunum, in vivo
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    By immunohistochemical methods, immunoreactive vasoactive intestinal polypeptide and immunoreactive substance P were localized to both nerve cell bodies and nerve fibers in the ferret intestine.
    1 context sentence
    Summary · context
    The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 05AnimalEndogenous levelAnimal study (in vivo)Other

    In the ferret intestine, VIP concentrations were similar to those in human intestine and much higher in the muscular layer than in the epithelial layer.

    In plain wordsIn ferrets, the body's own VIP was far more concentrated in the muscle layer of the intestine than in the lining.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableIntestinal VIP concentration by layer
    Study

    ferretn: not reported in source

    jejunum, in vivo
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    Determination of intestinal concentrations of vasoactive intestinal polypeptide and substance P in the ferret showed concentrations of these two neuropeptides that were similar to those in human intestine and demonstrated much higher concentrations of these substances in the muscular layer than in the epithelial layer.
    1 context sentence
    Summary · context
    The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.